Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
705 (USA) · Dr. Muller
consented 2013-06-23
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild ANXIETY — outcome: RECOVERED/RESOLVED; onset 2013-07-04 (study day 12.0); relationship: POSSIBLE
mild
assessed
Mild RASH ERYTHEMATOUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-22 (study day -1.0); relationship: PROBABLE
Data queries
No data queries.